Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.

International journal of cancer - 1 Apr 2017

Domagala Pawel, Hybiak Jolanta, Cybulski Cezary, Lubinski Jan

Abstract excerpt

BRCA1/2-associated breast cancers are sensitive to poly(ADPribose) polymerase (PARP) inhibitors and platinum compounds mainly due to their deficiency in DNA repair via homologous recombination (HR). However, approximately only 15% of triple-negative breast cancers (TNBCs) are BRCA1/2-associated. TNBCs that exhibit BRCAness (a phenotype reflecting impaired HR in BRCA1/2-negative tumors) are also regarded sensitive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Homologous Recombination
Share to Genes, BRCA1
Share to Genes, BRCA2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Registries

Share to Surveys and Questionnaires

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 27943282
DOI: 10.1002/ijc.30570

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.PMID 27943282Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?Semantic proximity Read ↗

Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.Semantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancerSemantic proximity Read ↗

Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.Semantic proximity Read ↗

Systemic therapy options in BRCA mutation-associated breast cancer.Semantic proximity Read ↗

Non-BRCA1/BRCA2 High-Risk Familial Breast Cancers are Not Associated with a High Prevalence of BRCAnessSemantic proximity Read ↗

BRCA1/2 testing: therapeutic implications for breast cancer managementSemantic proximity Read ↗

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.